- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Josh Marsh Discusses the Role of Technology, Automation in Patient Assistance Programs
Technology and automation within patient assistance programs can enhance the patient journey and assist pharmaceutical manufacturers at a lower cost, explained Josh Marsh, vice president of Sonexus at Cardinal Health.
Josh Marsh, vice president of Sonexus at Cardinal Health, says that innovations like technology and automation within patient assistance programs can help both patients and manufacturers.
Transcript
How have patient assistance programs in the pharmaceutical industry evolved in recent years?
I've definitely seen a shift over the past 5 to 7 years as a specialty space has grown; more products being launched, more of the patient population being positively impacted by these products coming to the market. I always say that historically, when a brand grew 10%, your patient service program added 10% of new FTEs [full-time equivalents] to the program to support it. Well, that gets very expensive as your brand grows in the market. So, what we've seen is by being able to implement more technology, more automation into the process, we can not only positively impact the patient journey, decreasing that turnaround time, but we're also able to do more for our manufacturers at a lower cost, which is always a goal as well.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More
